FDA (Taiwan) authorise Moderna’s Covid-19 mRNA vaccine targeting the SARS-COV-2 variant JN.1

Moderna, Inc., a pioneer in mRNA medicine, announced that Taiwan's Food & Drug Administration (FDA) has approved a new version of the Spikevax Covid-19 mRNA vaccine. This updated formulation targets the SARS-CoV-2 variant JN.1 and is approved for use in individuals aged six months and older to prevent Covid-19.

In April 2024, the World Health Organization's (WHO) Technical Advisory Group on Covid-19 Vaccine Composition (TAG-CO-VAC) recommended using a monovalent JN.1 lineage for Covid-19 vaccines.

Moderna's updated vaccine is currently under review by regulatory agencies globally, with decisions expected soon.

Moderna continues to lead in mRNA medicine, revolutionizing the development of treatments and vaccines to improve healthcare worldwide.